{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Ertumaxomab",
  "nciThesaurus": {
    "casRegistry": "509077-99-0",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A murine monoclonal antibody with two antigen-recognition sites: one for CD3, an antigen expressed on mature T cells, and one for HER-2-neu, a tumor-associated antigen that promotes tumor growth.  Ertumaxomab attaches to CD3-expressing T cells and HER-2-neu-expressing tumor cells, selectively cross-linking tumor and immunologic cells which results in the recruitment of cytotoxic T cells to the T cell/tumor cell aggregate.",
    "fdaUniiCode": "L5L45YGP1O",
    "identifier": "C2658",
    "preferredName": "Ertumaxomab",
    "semanticType": "Amino Acid, Peptide, or Protein",
    "subclassOf": [
      "C129822",
      "C1454"
    ],
    "synonyms": [
      "Anti-CD3 x anti-HER-2-neu Bispecific Monoclonal Antibody",
      "ERTUMAXOMAB",
      "Ertumaxomab"
    ]
  }
}